• Alias: SCH 66336
    • A synthetic tricyclic derivative of carboxamide that binds to and inhibits farnesyl transferase, an enzyme involved in the posttranslational modification and activation of RAS proteins
    • Currently no actively recruiting trials for cancer treatment in the United States
    • Recommended phase 2 dose: 200 mg PO b.i.d. on days 1 to 14 of a 28-day dosing regimen
    • Half-life: 3 to 7 hours
    • Common side effects: Fatigue, diarrhea, anorexia, nausea/vomiting, constipation, abdominal cramping, anemia, thrombocytopenia, neutropenia
    (Castaneda et al., 2011)
    Other topics in Targeted and Immunotherapy Agents